Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis-Reference-Cited by-同舟云学术

Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis

Published:2018-10-15 Issue:2 Volume:21 Page:340-348
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Cahn Avivit¹²^ORCID,Melzer-Cohen Cheli³,Pollack Rena¹²,Chodick Gabriel³⁴,Shalev Varda³⁴

Affiliation:

1. Diabetes Unit, Department of Endocrinology and Metabolism; Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine; Jerusalem Israel

2. Diabetes Clinic; Maccabi Healthcare Services; Jerusalem Israel

3. Maccabi Institute for Research and Innovation; Maccabi Healthcare Services; Tel-Aviv Israel

4. School of Public Health, Sackler Faculty of Medicine; Tel Aviv University; Tel-Aviv Israel

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13532/fullpdf

Reference17 articles.

1. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

2. Empagliflozin and progression of kidney disease in type 2 diabetes;Wanner;N Engl J Med,2016

3. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017

4. Canagliflozin slows progression of renal function decline independently of glycemic effects;Heerspink;J Am Soc Nephrol,2017

5. US Food and Drug Administration 2016 https://www.fda.gov/Drugs/DrugSafety/ucm505860.htm

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Renoprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)—A Narrative Review;International Journal of Molecular Sciences;2024-06-27

2. Key results from observational studies and real‐world evidence of sodium‐glucose cotransporter‐2 inhibitor effectiveness and safety in reducing cardio‐renal risk;Diabetes, Obesity and Metabolism;2024-06-10

3. Impact of empagliflozin on first and recurrent events leading to or prolonging hospitalisation in the EMPA-REG OUTCOME trial;Diabetes Research and Clinical Practice;2024-06

4. Acute kidney injury, renal impairment and renal failure associated with sodium glucose co‐transporter‐2 inhibitors in at‐risk groups: A systematic review;British Journal of Clinical Pharmacology;2024-05-24

5. The association between sodium glucose cotransporter‐2 inhibitors vs dipeptidyl peptidase‐4 inhibitors and renal outcomes in people discharged from hospital with type 2 diabetes: A population‐based cohort study;Journal of Diabetes;2024-04